Genmab A/S (GMAB)
29.98
+0.33
(+1.11%)
USD |
NASDAQ |
May 17, 16:00
29.96
-0.02
(-0.07%)
After-Hours: 20:00
Genmab Cash from Financing (TTM): -86.53M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -86.53M |
December 31, 2023 | -87.98M |
September 30, 2023 | -72.58M |
June 30, 2023 | -160.33M |
March 31, 2023 | -190.31M |
December 31, 2022 | -111.85M |
September 30, 2022 | -122.26M |
June 30, 2022 | -32.08M |
March 31, 2022 | -40.82M |
December 31, 2021 | -66.83M |
September 30, 2021 | -64.21M |
June 30, 2021 | -66.48M |
March 31, 2021 | -27.00M |
December 31, 2020 | 10.88M |
September 30, 2020 | 10.73M |
June 30, 2020 | 549.19M |
March 31, 2020 | 552.68M |
December 31, 2019 | 548.79M |
September 30, 2019 | 544.11M |
June 30, 2019 | 4.862M |
March 31, 2019 | 8.170M |
December 31, 2018 | -11.25M |
September 30, 2018 | -11.50M |
June 30, 2018 | -9.625M |
March 31, 2018 | -3.160M |
Date | Value |
---|---|
December 31, 2017 | 32.73M |
September 30, 2017 | 36.63M |
June 30, 2017 | 29.77M |
March 31, 2017 | 22.67M |
December 31, 2016 | 13.55M |
September 30, 2016 | 16.41M |
June 30, 2016 | 37.41M |
March 31, 2016 | 53.32M |
December 31, 2015 | 95.67M |
September 30, 2015 | 93.24M |
June 30, 2015 | 71.19M |
March 31, 2015 | 49.63M |
December 31, 2014 | 184.67M |
September 30, 2014 | 194.81M |
June 30, 2014 | 200.46M |
March 31, 2014 | 205.03M |
December 31, 2013 | 27.01M |
September 30, 2013 | 75.26M |
June 30, 2013 | 73.04M |
March 31, 2013 | 67.11M |
December 31, 2012 | 61.79M |
September 30, 2012 | -1.022M |
June 30, 2012 | -1.095M |
March 31, 2012 | -1.128M |
December 31, 2011 | -1.138M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-190.31M
Minimum
Mar 2023
552.68M
Maximum
Mar 2020
54.60M
Average
-52.52M
Median
Cash from Financing (TTM) Benchmarks
Ascendis Pharma A/S | 166.15M |
Novo Nordisk A/S | -10.04B |
Galecto Inc | 2.853M |
Evaxion Biotech AS | -- |
IO Biotech Inc | 71.86M |